Egret Therapeutics, a portfolio company of
Turret Capital Management, announces FDA Clearance of its IND
Application for EGT 101
NEW
YORK, Feb. 4, 2023 /PRNewswire/ -- Egret
Therapeutics, a clinical-stage biotechnology company focused on
developing transformative therapies for neurological conditions,
today announced that the U.S. Food and Drug Administration (FDA)
has cleared its Investigational New Drug (IND) application for EGT
101 that is being studied for the treatment of Delayed Cerebral
Ischemia (DCI) following aneurysmal subarachnoid hemorrhage. The
Phase I/II trial is expected to begin enrolling patients in
2023.
"We are thrilled to have received IND clearance for our program
in aneurysmal subarachnoid hemorrhage," said Daniel Chai, M.D., Co-Founder and Chief
Executive Officer of Egret Therapeutics. "Clearance of this IND is
a testament to the hard work and deep commitment from the Egret
team in bringing drugs to the market that will help patients," said
Henry Park, Chief Financial Officer
of Egret Therapeutics.
Among subarachnoid hemorrhage (SAH) patients who survive the
initial bleed of a ruptured aneurysm, delayed cerebral ischemia
(DCI) is the most important preventable cause of mortality and poor
neurological outcome. "DCI prevention has been the focus of SAH
research for decades, but few clinical options exist today. We are
excited to move forward in our clinical development of EGT 101 with
the hopes of bringing a therapy to patients where there is a high
unmet need," said Chris Jackson,
M.D., Co-Founder and Chief Medical Officer of Egret
Therapeutics.
About Egret Therapeutics
Egret Therapeutics is a clinical-stage biotherapeutics company.
The company is focused on developing products to address areas of
clinical unmet need in neurological diseases.
For more information, visit us at www.egrettherapeutics.com
View original
content:https://www.prnewswire.com/news-releases/egret-therapeutics-receives-fda-clearance-of-ind-application-for-egt-101-for-treatment-of-delayed-cerebral-ischemia-301738916.html
SOURCE Turret Capital Management